Eli Lilly's Foundayo Faces Sales Challenges Post FDA Approval
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: NASDAQ.COM
- Initial Prescription Struggles: Eli Lilly's Foundayo received only 1,390 prescriptions in its first week post-FDA approval, increasing to 3,707 in the second week, yet this pales in comparison to Novo Nordisk's Wegovy, which garnered 18,410 prescriptions, indicating a concerning market reception that could impact future sales expectations.
- Stock Price Decline Reflects Concerns: The disappointing initial sales performance led to a nearly 4% drop in Eli Lilly's stock price on Friday, reflecting investor skepticism about the new product's viability, which may result in short-term capital outflows and affect the company's market capitalization.
- Intensifying Market Competition: As Eli Lilly's first FDA-approved weight-loss pill, Foundayo faces formidable competition from Wegovy, which has already established a strong reputation and sales record, complicating Foundayo's market outlook and necessitating close monitoring of its subsequent performance.
- Long-Term Potential Remains: Despite Foundayo's poor initial sales data, Eli Lilly, as a major pharmaceutical company with a diverse product portfolio, has demonstrated potential in the weight-loss category with Zepbound's success, suggesting that investors should focus on long-term growth rather than short-term fluctuations.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 917.650
Low
950.00
Averages
1192
High
1500
Current: 917.650
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, and market products in a single business segment called human pharmaceutical products. The Company manufacture and distribute its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. The Company’s products are sold in approximately 90 countries. Its Cardiometabolic Health products Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Eli Lilly Stock Outlook Optimistic with Analysts' Upgrades
- Analyst Upgrades: Guggenheim raised Eli Lilly's price target from $1,163 to $1,183, indicating a 31% upside, while Morgan Stanley increased its target to $1,327, suggesting a 47% potential growth, reflecting optimism about the company's future performance.
- Initial Drug Performance: Despite Eli Lilly's newly approved diabetes pill Foundayo recording only 3,707 prescriptions in its second week, significantly trailing Novo's Wegovy, analysts remain positive about its long-term market potential, believing it can improve market share over time.
- Acquisition Strengthens Oncology Pipeline: Eli Lilly's recent $7 billion acquisition of Kelonia Therapeutics aims to bolster its oncology pipeline, which not only solidifies its position in cell therapy but may also drive future revenue growth through enhanced treatment offerings.
- Upcoming Earnings Expectations: Analysts anticipate that Eli Lilly will report a 38% revenue increase to $17.61 billion in its Q1 earnings on April 30, with expected earnings per share of $6.87, a significant rise from last year's figures, indicating a trend of ongoing performance improvement.
See More
Lilly and Novo Nordisk Compete in Oral Obesity Drug Market
- Market Performance Comparison: Lilly's oral obesity drug Foundayo garnered 3,707 prescriptions in its second week, significantly lower than Novo Nordisk's Wegovy, which achieved 18,410 prescriptions in the same period, indicating a weaker market acceptance for Lilly that could impact future sales performance.
- Prescription Growth Discrepancy: Foundayo only received 1,390 prescriptions in its debut week, while Wegovy reached 3,071 prescriptions in its first four days, highlighting Novo's clear advantage in market promotion and consumer acceptance, potentially leading to a loss of market share for Lilly.
- FDA Approval and Market Outlook: Foundayo was approved by the FDA earlier this month for use alongside a reduced-calorie diet and increased physical activity; however, despite showing significant weight loss in clinical trials, the market response has not met expectations, which may affect the company's long-term strategy.
- Investor Sentiment Shift: Although Lilly's stock fell 4% on Friday, retail sentiment on Stocktwits shifted from 'neutral' to 'bullish', indicating market expectations for future potential, which may provide support for the company's subsequent performance.
See More
Eli Lilly's Foundayo Faces Sales Challenges Post FDA Approval
- Initial Prescription Struggles: Eli Lilly's Foundayo received only 1,390 prescriptions in its first week post-FDA approval, increasing to 3,707 in the second week, yet this pales in comparison to Novo Nordisk's Wegovy, which garnered 18,410 prescriptions, indicating a concerning market reception that could impact future sales expectations.
- Stock Price Decline Reflects Concerns: The disappointing initial sales performance led to a nearly 4% drop in Eli Lilly's stock price on Friday, reflecting investor skepticism about the new product's viability, which may result in short-term capital outflows and affect the company's market capitalization.
- Intensifying Market Competition: As Eli Lilly's first FDA-approved weight-loss pill, Foundayo faces formidable competition from Wegovy, which has already established a strong reputation and sales record, complicating Foundayo's market outlook and necessitating close monitoring of its subsequent performance.
- Long-Term Potential Remains: Despite Foundayo's poor initial sales data, Eli Lilly, as a major pharmaceutical company with a diverse product portfolio, has demonstrated potential in the weight-loss category with Zepbound's success, suggesting that investors should focus on long-term growth rather than short-term fluctuations.
See More
Eli Lilly's New Drug Sales Underwhelm Investors
- New Drug Sales Performance: Eli Lilly's weight loss pill Foundayo was prescribed only 1,390 times in its first week post-FDA approval, increasing to 3,707 in the second week, yet this pales in comparison to rival Novo Nordisk's Wegovy, which saw 18,410 prescriptions in its second week, indicating a significant market acceptance gap.
- Stock Price Fluctuation: Concerns over Foundayo's sales outlook led to a nearly 4% drop in Eli Lilly's stock price during the trading session, reflecting investor skepticism about the new product's potential, which could impact the company's future financing and investment strategies.
- Competitive Market Pressure: While Eli Lilly has seen success with Zepbound, the disappointing initial performance of Foundayo raises concerns about its competitive position in the rapidly growing weight loss market, necessitating close monitoring of its subsequent sales data.
- Long-Term Outlook: Eli Lilly noted that the sales data for Foundayo may require time for a comprehensive assessment; despite the initial underperformance, the company's diversified strategy in drug development and market positioning still provides a stable growth foundation.
See More
US Stocks Close Higher: S&P 500 Hits All-Time High
- S&P 500 Hits Record High: The S&P 500 index rose by 0.80%, closing at an all-time high, reflecting market optimism about economic recovery, particularly driven by technology stocks, which further solidifies investor confidence.
- Intel's Strong Performance: Intel's stock surged over 23% after forecasting Q2 revenue between $13.8 billion and $14.8 billion, significantly exceeding the $13.04 billion expectation, indicating strong confidence in the semiconductor industry's potential driven by artificial intelligence, which may spark increased investment in the sector.
- Consumer Confidence Rebounds: The University of Michigan's consumer sentiment index was revised upward to 49.8, surpassing the expected 48.5, suggesting an increase in consumer confidence regarding economic prospects, which could drive consumer spending and economic growth.
- International Dynamics Affecting Markets: Progress in US-Iran negotiations has boosted market sentiment; despite tensions in the Strait of Hormuz, optimism about future talks may alleviate energy price pressures and promote stock market gains.
See More
Tech Earnings Week to Test Market Confidence
- Strong Market Performance: The S&P 500 and Nasdaq Composite closed at record highs on Friday, primarily driven by strong performances from chipmakers like Intel, indicating that stocks related to AI infrastructure are propelling market gains.
- Importance of Earnings Week: Cramer emphasized that next week will be the most critical for the tech sector this quarter, as it will reveal whether the market's confidence in high-valuation tech stocks is overly optimistic, particularly after reports from Verizon and Corning.
- Leading Industry Performers: Cramer described Nucor as the best industrial company in the market, with its earnings report likely to attract investor attention, while Bloom Energy could see a
See More
Eli Lilly Stock Outlook Optimistic with Analysts' Upgrades
- Analyst Upgrades: Guggenheim raised Eli Lilly's price target from $1,163 to $1,183, indicating a 31% upside, while Morgan Stanley increased its target to $1,327, suggesting a 47% potential growth, reflecting optimism about the company's future performance.
- Initial Drug Performance: Despite Eli Lilly's newly approved diabetes pill Foundayo recording only 3,707 prescriptions in its second week, significantly trailing Novo's Wegovy, analysts remain positive about its long-term market potential, believing it can improve market share over time.
- Acquisition Strengthens Oncology Pipeline: Eli Lilly's recent $7 billion acquisition of Kelonia Therapeutics aims to bolster its oncology pipeline, which not only solidifies its position in cell therapy but may also drive future revenue growth through enhanced treatment offerings.
- Upcoming Earnings Expectations: Analysts anticipate that Eli Lilly will report a 38% revenue increase to $17.61 billion in its Q1 earnings on April 30, with expected earnings per share of $6.87, a significant rise from last year's figures, indicating a trend of ongoing performance improvement.
See More
Lilly and Novo Nordisk Compete in Oral Obesity Drug Market
- Market Performance Comparison: Lilly's oral obesity drug Foundayo garnered 3,707 prescriptions in its second week, significantly lower than Novo Nordisk's Wegovy, which achieved 18,410 prescriptions in the same period, indicating a weaker market acceptance for Lilly that could impact future sales performance.
- Prescription Growth Discrepancy: Foundayo only received 1,390 prescriptions in its debut week, while Wegovy reached 3,071 prescriptions in its first four days, highlighting Novo's clear advantage in market promotion and consumer acceptance, potentially leading to a loss of market share for Lilly.
- FDA Approval and Market Outlook: Foundayo was approved by the FDA earlier this month for use alongside a reduced-calorie diet and increased physical activity; however, despite showing significant weight loss in clinical trials, the market response has not met expectations, which may affect the company's long-term strategy.
- Investor Sentiment Shift: Although Lilly's stock fell 4% on Friday, retail sentiment on Stocktwits shifted from 'neutral' to 'bullish', indicating market expectations for future potential, which may provide support for the company's subsequent performance.
See More
Eli Lilly's Foundayo Faces Sales Challenges Post FDA Approval
- Initial Prescription Struggles: Eli Lilly's Foundayo received only 1,390 prescriptions in its first week post-FDA approval, increasing to 3,707 in the second week, yet this pales in comparison to Novo Nordisk's Wegovy, which garnered 18,410 prescriptions, indicating a concerning market reception that could impact future sales expectations.
- Stock Price Decline Reflects Concerns: The disappointing initial sales performance led to a nearly 4% drop in Eli Lilly's stock price on Friday, reflecting investor skepticism about the new product's viability, which may result in short-term capital outflows and affect the company's market capitalization.
- Intensifying Market Competition: As Eli Lilly's first FDA-approved weight-loss pill, Foundayo faces formidable competition from Wegovy, which has already established a strong reputation and sales record, complicating Foundayo's market outlook and necessitating close monitoring of its subsequent performance.
- Long-Term Potential Remains: Despite Foundayo's poor initial sales data, Eli Lilly, as a major pharmaceutical company with a diverse product portfolio, has demonstrated potential in the weight-loss category with Zepbound's success, suggesting that investors should focus on long-term growth rather than short-term fluctuations.
See More
Eli Lilly's New Drug Sales Underwhelm Investors
- New Drug Sales Performance: Eli Lilly's weight loss pill Foundayo was prescribed only 1,390 times in its first week post-FDA approval, increasing to 3,707 in the second week, yet this pales in comparison to rival Novo Nordisk's Wegovy, which saw 18,410 prescriptions in its second week, indicating a significant market acceptance gap.
- Stock Price Fluctuation: Concerns over Foundayo's sales outlook led to a nearly 4% drop in Eli Lilly's stock price during the trading session, reflecting investor skepticism about the new product's potential, which could impact the company's future financing and investment strategies.
- Competitive Market Pressure: While Eli Lilly has seen success with Zepbound, the disappointing initial performance of Foundayo raises concerns about its competitive position in the rapidly growing weight loss market, necessitating close monitoring of its subsequent sales data.
- Long-Term Outlook: Eli Lilly noted that the sales data for Foundayo may require time for a comprehensive assessment; despite the initial underperformance, the company's diversified strategy in drug development and market positioning still provides a stable growth foundation.
See More
US Stocks Close Higher: S&P 500 Hits All-Time High
- S&P 500 Hits Record High: The S&P 500 index rose by 0.80%, closing at an all-time high, reflecting market optimism about economic recovery, particularly driven by technology stocks, which further solidifies investor confidence.
- Intel's Strong Performance: Intel's stock surged over 23% after forecasting Q2 revenue between $13.8 billion and $14.8 billion, significantly exceeding the $13.04 billion expectation, indicating strong confidence in the semiconductor industry's potential driven by artificial intelligence, which may spark increased investment in the sector.
- Consumer Confidence Rebounds: The University of Michigan's consumer sentiment index was revised upward to 49.8, surpassing the expected 48.5, suggesting an increase in consumer confidence regarding economic prospects, which could drive consumer spending and economic growth.
- International Dynamics Affecting Markets: Progress in US-Iran negotiations has boosted market sentiment; despite tensions in the Strait of Hormuz, optimism about future talks may alleviate energy price pressures and promote stock market gains.
See More
Tech Earnings Week to Test Market Confidence
- Strong Market Performance: The S&P 500 and Nasdaq Composite closed at record highs on Friday, primarily driven by strong performances from chipmakers like Intel, indicating that stocks related to AI infrastructure are propelling market gains.
- Importance of Earnings Week: Cramer emphasized that next week will be the most critical for the tech sector this quarter, as it will reveal whether the market's confidence in high-valuation tech stocks is overly optimistic, particularly after reports from Verizon and Corning.
- Leading Industry Performers: Cramer described Nucor as the best industrial company in the market, with its earnings report likely to attract investor attention, while Bloom Energy could see a
See More
